Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
157M
-
Number of holders
-
155
-
Total 13F shares, excl. options
-
88.8M
-
Shares change
-
+17.6M
-
Total reported value, excl. options
-
$377M
-
Value change
-
+$45.4M
-
Put/Call ratio
-
0.35
-
Number of buys
-
89
-
Number of sells
-
-72
-
Price
-
$4.25
Significant Holders of TG THERAPEUTICS, INC. - Common Stock (TGTX) as of Q2 2022
213 filings reported holding TGTX - TG THERAPEUTICS, INC. - Common Stock as of Q2 2022.
TG THERAPEUTICS, INC. - Common Stock (TGTX) has 155 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 88.8M shares
of 157M outstanding shares and own 56.45% of the company stock.
Largest 10 shareholders include STATE STREET CORP (14.2M shares), VANGUARD GROUP INC (13M shares), MAVERICK CAPITAL LTD (6.75M shares), MILLENNIUM MANAGEMENT LLC (4.96M shares), WELLINGTON MANAGEMENT GROUP LLP (4.19M shares), 683 Capital Management, LLC (3.3M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.68M shares), GEODE CAPITAL MANAGEMENT, LLC (2.32M shares), FEDERATED HERMES, INC. (2.23M shares), and Assenagon Asset Management S.A. (2.09M shares).
This table shows the top 155 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.